ARDX News

Ardelyx Receives New Patent for Tenapanor

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting